SciSparc subsidiary NeuroThera reports enrollment momentum in SCI-210 trial
SciSparc says its NeuroThera Labs has achieved significant enrollment momentum in its SCI-210 autism clinical trial.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.